Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
A large number of oncolytic viral vectors are currently under clinical development for cancer therapy. Herpes simplex virus type 1 (HSV-1) has demonstrated particular promise in this field, showing genetically engineered selective tumor replication and cytotoxicity in a wide variety of tumor types, without damaging healthy tissues. Enhanced activity has been observed when a range of therapeutic genes has been inserted into various oncolytic HSV genomes. Here, we discuss methods used to develop and characterize an oncolytic HSV virus that combines expression of a highly potent prodrug activating gene (yeast cytosine deaminase/uracil phosphoribosyltransferase fusion [Fcy::Fur]) and the fusogenic glycoprotein from gibbon ape leukemia virus (GALV) for enhanced local tumor control.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/978-1-59745-561-9_29 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antitumor power of oncolytic HSV engineered with IL-12 and IL-15.
Mol Ther Oncol
September 2025
College of Life Science and Technology, Xinjiang University, Urumqi, Xinjiang 830046, China.
Oncolytic herpes simplex virus type 1 (HSV-1) directly targets and destroys tumor cells while selectively infecting surrounding tumor tissue and releasing progeny viruses to continue the attack. We engineered the replicative HSV-1 vector, including the oncolytic HSV-1 (oHSV) with deleted inverted repeat and α47 gene, and then the oHSV expressing interleukin-15 (IL-15) gene and the oHSV expressing IL-15 and interleukin-12 (IL-12) gene. We evaluated the titer and growth characteristics of the oHSV-1 in Vero and cancer cell lines.
View Article and Find Full Text PDFOncolytic Therapies for Glioblastoma: Advances, Challenges, and Future Perspectives.
Cancers (Basel)
August 2025
Department of Neurosurgery, University of Wisconsin School of Medicine, Madison, WI 53706, USA.
Glioblastoma (GBM) remains one of the most aggressive and treatment-resistant brain tumors, necessitating novel therapeutic approaches. Oncolytic treatments, particularly oncolytic viruses (OVs), have emerged as promising candidates by selectively infecting and lysing tumor cells while stimulating anti-tumor immunity. Various virus-based therapies are under investigation, including genetically engineered herpes simplex virus (HSV), adenovirus, poliovirus, reovirus, vaccinia virus, measles virus, and Newcastle disease virus, each exploiting unique tumor-selective mechanisms.
View Article and Find Full Text PDFCancer interrupted: A story of oncolytic HSV-induced killing.
Mol Ther
September 2025
Department of Pathology, Medical College of Georgia at Augusta University, Augusta, GA, USA; Georgia Cancer Center at Augusta University, Augusta, GA, USA. Electronic address:
Oncolytic HSV and cancer drug interactions: Current clinical status and future directions.
Mol Ther
July 2025
Department of Pathology, Medical College of Georgia and Georgia Cancer Center, Augusta University, Augusta, GA 30912, USA. Electronic address:
Oncolytic herpes simplex viruses (oHSVs) are engineered to target and replicate specifically in tumor cells, minimizing damage to normal tissues. This live virus biotherapy entails direct tumor cell killing followed by stimulation of antitumor immunity, leading to abscopal effects in untreated lesions. Currently, there are two clinically approved oHSV biotherapeutics: Imlygic, marketed by Amgen for the treatment of advanced melanoma in the United States and Europe, and Delytact, conditionally approved for recurrent brain tumors in Japan.
View Article and Find Full Text PDFGnostic and agnostic immunotherapy by tropism-retargeted herpes simplex virus without direct tumor treatment.
J Immunother Cancer
July 2025
Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Background: Cancer immunotherapy includes vaccines generated through distinct approaches, each with advantages and limitations. Those made of autologous or allogeneic whole cells do not require prior identification of antigens, that is, immunize against undetermined (agnostic) tumor antigens. However, they often exhibit low adjuvanticity and modest antigenicity.
View Article and Find Full Text PDF